Biogen Buys Apellis for $5.6B to Expand Kidney Drugs

Bloomberg
Loading video player...
Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
Bloomberg
Written by Bloomberg
Share

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company's largest-ever acquisitions.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.